ProMIS Neurosciences Inc.
PMN evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $121.6M
- Lead Asset:
- pmn310 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for PMN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PMN
ProMIS Neurosciences Inc. (PMN) is a clinical-stage biotechnology company developing monoclonal antibodies targeting toxic misfolded proteins in neurodegenerative diseases, with lead candidate PMN310 for Alzheimer's disease currently in a Phase 1b trial.
Key risk: No product revenue
BioSniper Score
Based on 4 of 6 signals
Market Cap
$121.6M
Cash Runway
—
Lead Asset
pmn310 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for ProMIS Neurosciences Inc..
ProMIS Neurosciences Inc. (PMN) is a clinical-stage biotechnology company developing monoclonal antibodies targeting toxic misfolded proteins in neurodegenerative diseases, with lead candidate PMN310 for Alzheimer's disease currently in a Phase 1b trial.
- Lead candidate PMN310 is a monoclonal antibody designed to selectively target toxic amyloid-beta oligomers in Alzheimer's disease [sec_mda · as of 2026-05-12].
- PRECISE-AD Phase 1b trial fully enrolled; six-month interim data expected Q2 2026 and final top-line results Q4 2026 [sec · filed 2025-09-03].
- Cash and equivalents of $53.4M as of 2026-06-30 [sec].
- Net loss of $11.7M for the period ended 2026-06-30 [sec].
- FDA granted Fast Track Designation for PMN310 in Alzheimer's disease [news · published 2025-08-13].
What works
- PMN310 has shown a favorable safety profile with no treatment-related serious adverse events and no cases of amyloid-related imaging abnormalities (ARIA) reported to date [news · published 2026-03-25].
- The company's technology platform uses protein biology, physics, and supercomputing to selectively target toxic misfolded proteins, potentially reducing interference with normal protein function [sec_mda · as of 2026-05-12].
- FDA Fast Track Designation for PMN310 may enable priority review and more frequent interactions with the agency [news · published 2025-08-13].
- Cash runway extended through 2027 following $53.4M in cash as of mid-2026 [news · published 2026-08-14].
What to weigh
- The company has not yet generated product revenue and may not become profitable even if product sales begin [sec_mda · as of 2026-08-13].
- Operating loss of $40.2M for the year ended December 31, 2025, and an accumulated deficit [sec_mda · as of 2026-03-25].
- If additional capital is not raised, the company may need to significantly delay, reduce, or eliminate development of product candidates [sec_mda · as of 2026-08-13].
- The company's ability to continue as a going concern has been previously questioned due to limited cash runway [sec_mda · as of 2025-08-13].
From the filings
Quoted directly from source documents.
PMN310 selectively targets toxic amyloid-beta oligomers
“PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta.”
SEC MD&A · May 12, 2026
No ARIA cases observed in PRECISE-AD trial
“no cases of amyloid-related imaging abnormalities observed to date”
SEC filings · September 3, 2025
FDA Fast Track Designation for PMN310
“U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease”
News · August 13, 2025
Catalyst timeline
- 2023-11-18 · Phase 1a start (PMN310 single ascending dose in healthy volunteers) — Initiation of first-in-human study for PMN310.
- 2024-12-13 · Phase 1b start (PMN310 multiple ascending dose in early Alzheimer's patients) — Start of PRECISE-AD trial in patients with early Alzheimer's disease.
Risks & what to watch (4)›
Key risks
- No product revenue — Company has no approved products and may never achieve profitability even if sales begin [sec_mda · as of 2026-08-13].
- Capital dependency — Failure to raise capital could force significant delays or termination of development programs [sec_mda · as of 2026-08-13].
- Accumulated deficit — Operating loss of $40.2M in 2025 and ongoing accumulated deficit [sec_mda · as of 2026-03-25].
- Clinical trial uncertainty — Phase 1b data not yet released; efficacy and safety beyond current cohorts unknown [sec · filed 2025-09-03].
What to watch
- Six-month interim data from PRECISE-AD Phase 1b trial expected Q2 2026 [sec · filed 2025-09-03].
- Final top-line results from PRECISE-AD anticipated Q4 2026 [sec · filed 2025-09-03].
- Cash runway and any additional financing rounds, given prior going-concern warnings [news · published 2026-08-14].
- Progress of second lead candidate PMN267 for ALS [sec_mda · as of 2026-05-12].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated September 24, 2026 · How we verify sources →
Run ProMIS Neurosciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ProMIS Neurosciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.15 · 0% dilution
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$78.0M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 1,292,757 | $16.4M |
| deep track capital, lp | 835,655 | $10.6M |
| wellington management group llp | 696,378 | $8.8M |
| trails edge capital partners, lp | 557,103 | $7.1M |
| ally bridge group (ny) llc | 414,219 | $5.3M |
| woodline partners lp | 395,295 | $5.0M |
| great point partners llc | 371,402 | $4.7M |
| yu fan | 329,760 | $4.2M |
| sphera funds management ltd. | 325,591 | $4.1M |
| squadron capital management llc | 324,977 | $4.1M |
Showing top 10 of 25 institutional holders of ProMIS Neurosciences Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 1.6%
- Days to cover
- 3.5
- Shares short
- 138,078
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PMN short interestGovernance
Frequently asked questions
What is the AI investment thesis for ProMIS Neurosciences Inc.?
ProMIS Neurosciences Inc. (PMN) is a clinical-stage biotechnology company developing monoclonal antibodies targeting toxic misfolded proteins in neurodegenerative diseases, with lead candidate PMN310 for Alzheimer's disease currently in a Phase 1b trial.
What is ProMIS Neurosciences Inc.'s lead drug candidate?
ProMIS Neurosciences Inc.'s most advanced tracked candidate is pmn310 (Phase 1) for Alzheimer Disease, Early Onset; Healthy Participants.
Who is the CEO of ProMIS Neurosciences Inc.?
Mr. Neil K. Warma M.B.A. is the chief executive officer of ProMIS Neurosciences Inc. (PMN).
Where is ProMIS Neurosciences Inc. headquartered?
ProMIS Neurosciences Inc. (PMN) is headquartered in Toronto, ON, Canada.
What therapeutic areas does ProMIS Neurosciences Inc. focus on?
ProMIS Neurosciences Inc. develops therapies across Neurology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.